IsomAb

IsomAb Ltd is a UK-based biotechnology company developing isoform-specific disease-modifying antibody treatments for serious and life-threatening diseases. Their initial focus is on peripheral ischemia, with a lead antibody, ISM-001, aimed at treating peripheral arterial disease, particularly in patients with metabolic syndrome and Type II diabetes.

Buy Funded Startups lists

Funding Round: Seed

Funding Amount: £7.5M

Date: 20-Feb-2024

Investors: Broadview Ventures, SCVC, MEIF Proof of Concept & Early Stage Fund

Markets: Biotechnology, Pharmaceuticals, Biotechnology Research

HQ: Nottingham, England, United Kingdom

Founded: 2022

Website: https://www.isomab.bio/

LinkedIn: https://uk.linkedin.com/company/isomab-ltd

Twitter:

Instagram: